Page 326 - Read Online

Page 16 of 17 Singh et al. Vessel Plus 2018;2:33 I http://dx.doi.org/10.20517/2574-1209.2018.28

94. Wahlers T, Cremer J, Fleguth HG, Jurmann M, Herrmann G, et al. Adjusted triple drug immunosuppression and kidney function
following heart transplantation. Transplant Proc 1989;21:2492-3.
95. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs.
cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377-86.
96. Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, et al. Everolimus is associated with a reduced incidence of cytomegalovirus
infection following de novo cardiac transplantation. Transpl Infect Dis 2013;15:150-62.
97. Euvrard S, Boissonnat P, Roussoulières A, Kanitakis J, Decullier E, et al. Effect of everolimus on skin cancers in calcineurin inhihitor-
treated heart transplant recipients. Transpl Int 2010;23:855-7.
98. Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a
randomized, multicenter trial. Am J Transplant 2013;13:1203-16.
99. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, et al. The 2016 international society for heart lung transplantation listing
criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1-23.
100. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, et al. 2016 ESC guidelines for the diagnosis and treatment of acute
and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society
of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
2016;37:2129-200.
101. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy
for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of
Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation
2016;134:e282-93.
102. Dorent R, Gandjbakhch E, Goéminne C, Ivanes F, Sebbag L, et al. Assessment of potential heart donors: a statement from the French
heart transplant community. Arch Cardiovasc Dis 2017; doi: 10.1016/j.acvd.2017.12.001.
103. Copeland JG. Only optimal donors should be accepted for heart transplantation: protagonist. J Heart Lung Transplant 1995;14:1038-42.
104. Brock MV, Salazar JD, Cameron DE, Baumgartner WA, Conte JV. The changing profile of the cardiac donor. J Heart Lung Transplant
2001;20:1005-9.
105. NHS Blood and Transplant. Transplant Activity in the UK, 2016-2017. NHS Blood and Transplant; 2017.
106. Cooper DK, Keogh AM, Brink J, Corris PA, Klepetko W, et al. Report of the Xenotransplantation Advisory Committee of the
International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment
of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant 2000;19:1125-65.
107. Thompson JF, Wood RF, Cahill AP, Franklin PM, Morris PJ. Kidney transplantation and seat belt legislation. BMJ (Clinical research ed)
1983;287:1260-1.
108. Calil AM, Sallum EA, Domingues Cde A, Nogueira Lde S. Mapping injuries in traffic accident victims: a literature review. Rev Lat Am
Enfermagem 2009;17:120-5.
109. Mercer P, Sharples L, Edmunds J, Gittins R, Baines J, et al. Evaluating the donor pool: impact of using hearts from donors over the age
of 49 years. Transplant Proc 1997;29:3293-6.
110. Young JB. Age before beauty: the use of “older” donor hearts for cardiac transplantation. J Heart Lung Transplant 1999;18:488-91.
111. Silva SFR, Silva SL, Nascimento AC, Parente MM, Albuquerque CA, et al. Profile of organ donors in Ceará, northeastern Brazil, from
1998 to 2012. Transplant Proc 2014;46:1692-4.
112. Rodrigues SdLL, Ferraz Neto JB-HdE, Sardinha LAdC, Araujo S, Zambelli HJL, et al. Profile of effective donors from organ and tissue
procurement services. Rev Bras Ter Intensiva 2014;26:21-7.
113. Drinkwater DC, Laks H, Blitz A, Kobashigawa J, Sabad A, et al. Outcomes of patients undergoing transplantation with older donor
hearts. J Heart Lung Transplant 1996;15:684-91.
114. Bennett LE, Edwards EB, Hosenpud JD. Transplantation with older donor hearts for presumed “stable” recipients: an analysis of the
Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. J Heart Lung
Transplant 1998;17:901-5.
115. Massad MG, Smedira NG, Hobbs RE, Hoercher K, Vandervoort P, et al. Bench repair of donor mitral valve before heart transplantation.
Ann Thorac Surg 1996;61:1833-5.
116. Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, et al. The use of donor hearts with left ventricular hypertrophy. J Heart Lung
Transplant 2000;19:496-503.
117. Hornik L, Tenderich G, Wlost S, Zittermann A, Minami K, et al. Organs from donors with primary brain malignancy: the fate of cardiac
allograft recipients. Transplant Proc 2004;36:3133-7.
118. Banner NR, Bonser RS, Clark AL, Clark S, Cowburn PJ, et al. UK guidelines for referral and assessment of adults for heart
transplantation. Heart 2011;97:1520-7.
119. Stewart GC, Mehra MR. A history of devices as an alternative to heart transplantation. Heart Fail Clin 2014;10:S1-12.
120. Wilhelm MJ. Long-term outcome following heart transplantation: current perspective. J Thorac Dis 2015;7:549-51.
121. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, et al. The registry of the international society for heart and lung
transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant
2014;33:996-1008.